Taysha gene therapies to participate in upcoming june investor healthcare conferences

Dallas--(business wire)--taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivitol-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced its participation in a virtual fireside chat for the jefferies virtual healthcare conference, goldman sachs 42nd annual global healthcare conference, and the jmp securities
TSHA Ratings Summary
TSHA Quant Ranking